irinotecan + nogitecan + amrubicin + paclitaxel

This is a **combination chemotherapy regimen** composed of four distinct small-molecule antineoplastic agents: irinotecan, nogitecan, amrubicin, and paclitaxel. - **Irinotecan** is a topoisomerase I inhibitor, routinely used for various solid tumors including lung and colorectal cancers, acting by preventing DNA religation and inducing DNA damage and cell death in proliferating tumor cells. - **Nogitecan** (also known as ST1481 or NK-611) is another topoisomerase I inhibitor, used predominantly in clinical studies in Japan for malignancies such as small cell lung cancer and ovarian cancer. - **Amrubicin** is a synthetic anthracycline that inhibits topoisomerase II, disrupting DNA replication and transcription, and is used mainly in Japan for the treatment of small cell lung cancer. - **Paclitaxel** is a microtubule stabilizer (taxane class), inhibiting cell division by stabilizing tubulin polymerization. The rationale for combining agents with different mechanisms (topoisomerase I and II inhibitors and a microtubule agent) is to achieve synergistic cytotoxic effects and overcome resistance. Clinical trials have explored various double and triple combinations of these agents (e.g., irinotecan + paclitaxel, amrubicin + paclitaxel), but no published regimen employing all four drugs together in a single combination was identified.